Moving beyond association: the imperative for mechanistic and longitudinal research on body composition and bone quality in diabetic osteopathy Authors: DuJiang Yang, GuoYou Wang Published: 2025 ABSTRACT AbstractIn their cross-sectional study, Sun et al. (Aging Clin Exp Res. 2025) provide valuable evidence that the coexistence of high body fat and low muscle mass is associated with lower bone mineral density (BMD) in postmenopausal women with type 2 diabetes (T2D). While their work importantly identifies this “sarcopenic obesity” phenotype as a risk factor, our letter offers a critical appraisal to guide future research. We argue that the sole reliance on DXA-derived areal BMD is a significant limitation, as it fails to capture the deficits in bone quality (e.g., microarchitecture, material properties) that underpin the well-known paradox of increased fracture risk at normal or elevated BMD in T2D. Furthermore, the cross-sectional design and lack of biochemical data (e.g., on inflammation, adipokines, bone turnover markers) preclude any causal or mechanistic inferences about how this body composition profile affects bone.We contend that the operational definitions of sarcopenia and obesity based solely on quantity, without assessing muscle function or fat distribution, lack phenotypic precision. Moving forward, the field must adopt longitudinal designs that integrate advanced imaging (e.g., HR-pQCT) and deep metabolic phenotyping to elucidate the underlying pathways. Ultimately, this is essential for developing targeted interventions that address the intertwined pathologies of muscle, fat, and bone in this vulnerable population. To the editor, We read with great interest the recent study by Sun et al. (Aging Clin Exp Res. 2025;37(1):266) [1], which investigated the impact of high body fat and low muscle mass on bone mineral density (BMD) in postmenopausal women with type 2 diabetes (T2D). The authors adeptly highlight the paradox of bone fragility in T2D, challenging the conventional view of obesity as universally protective for bone. Their findings, suggesting that the sarcopenic obesity phenotype is associated with lower BMD and higher osteoporosis risk, represent a significant step toward a more nuanced understanding of metabolic bone disease. However, as we look to the future, several methodological and conceptual aspects of this research merit deeper scrutiny to guide the field toward more mechanistic and clinically impactful discoveries. 1. The DXA Paradox: The Illusion of Bone Strength in T2D. A primary critique centers on the sole reliance on Dual-energy X-ray Absorptiometry (DXA)-derived areal BMD (aBMD) as the primary endpoint. It is now well-established that T2D is characterized by a disproportionate increase in fracture risk despite normal or even elevated aBMD. This discrepancy arises because aBMD fails to capture critical determinants of bone quality, including bone microarchitecture, material properties, and turnover rate – all of which can be adversely affected by the diabetic milieu [1, 2]. The study by Sun et al. reports higher BMD in the obesity-alone group, a finding consistent with earlier work such as that by Li et al. However, this may create a misleading sense of skeletal security. The “high fat, low muscle” phenotype identified is likely a surrogate for a more sinister metabolic syndrome, characterized by chronic inflammation, insulin resistance, and accumulation of advanced glycation end-products (AGEs). These factors are known to impair bone remodeling and compromise collagen cross-linking, leading to brittle bone that is prone to fracture despite a normal DXA reading. Therefore, the observed association between sarcopenic obesity and lower aBMD might only represent the tip of the iceberg. The true clinical threat may lie in the much larger population of T2D patients with preserved aBMD but severely compromised bone quality. Future research must transition from DXA-based phenotyping to modalities like High-Resolution peripheral Quantitative Computed Tomography (HR-pQCT), which can directly assess trabecular and cortical microarchitecture, providing a far more accurate picture of bone strength [1, 2]. 2. Operational Definitions: The Need for Phenotypic Precision. The study’s use of appendicular skeletal muscle index (ASMI) and body fat percentage (BFP) to define sarcopenia and obesity is pragmatic but potentially oversimplified. The field lacks consensus on universally applicable DXA-derived cut-off points for these conditions, particularly in diverse ethnic populations with T2D. This ambiguity can lead to misclassification and dilute the true effect size of the sarcopenic obesity phenotype [2]. More importantly, these definitions are primarily quantitative and do not capture qualitative aspects. For instance, myosteatosis—the infiltration of muscle by fat—is a key feature of dysfunctional muscle in metabolic disease and is independently associated with poor physical performance and insulin resistance [3]. A low ASMI combined with high myosteatosis may represent a far greater threat to bone health than low ASMI alone, as it reflects a more profound state of metabolic dysregulation. Future studies should integrate measures of muscle function (e.g., grip strength, gait speed) and quality (e.g., via CT or MRI) to define a truly dysfunctional musculoskeletal phenotype. This would align with the concept of intrinsic capacity as proposed by the WHO, which encompasses both physical and mental capacities and is a stronger predictor of health outcomes than chronological age alone [2, 3]. 3. The Cross-Sectional Conundrum and the Mechanistic Black Box. The cross-sectional design, acknowledged by the authors, is a fundamental limitation that precludes causal inference. The critical question remains: does the sarcopenic obesity phenotype directly cause bone deterioration, or is it merely a marker of shared underlying pathologies? The absence of biochemical data represents a significant missed opportunity to explore mechanism. The diabetic state is characterized by altered secretion of adipokines (e.g., leptin, adiponectin), myokines (e.g., myostatin, irisin), and pro-inflammatory cytokines (e.g., IL-6, TNF-α), all of which have direct and indirect effects on bone cells. Furthermore, bone turnover markers (BTMs) such as osteocalcin and PTH are often suppressed in T2D, indicating low bone formation, a key mechanism for poor bone quality [3]. The inclusion of these mediators in a longitudinal study design is essential to move beyond association and establish a causal pathway. For example, a prospective study could test whether a decline in muscle mass and function precedes a decline in BMD and an increase in fracture risk, and whether this sequence is mediated by specific inflammatory or metabolic biomarkers [3, 4]. 4. From Observation to Intervention: The Unexplored Frontier. Finally, the study stops short of exploring the interventional implications of its findings. If sarcopenic obesity is a key driver of skeletal fragility in T2D, then combined interventions targeting both sarcopenia and obesity should be the logical next step [5]. While exercise therapy is recognized as a cornerstone for managing both osteoporosis and sarcopenia, the optimal “prescription”—the type, intensity, and frequency of exercise—for postmenopausal women with T2D and this specific body composition phenotype remains unknown. Similarly, nutritional strategies that go beyond caloric restriction to specifically preserve muscle mass (e.g., high-protein diets, leucine supplementation, vitamin D) while reducing fat mass need to be tested. The “black box” of multi-component interventions, as highlighted in other fields, must be opened to identify the most effective elements [4, 5]. Conclusion In summary, Sun et al. have successfully identified a high-risk body composition phenotype within a complex clinical population. Their work provides a crucial foundation, challenging us to move beyond simple anthropometrics and BMD measurements. The path forward lies in longitudinal studies that incorporate deep phenotyping of the metabolic milieu, advanced bone imaging, and functional assessments. Only through such a multi-faceted approach can we hope to unravel the intricate web of mechanisms linking muscle, fat, and bone in T2D and pave the way for mechanistically informed and personalized fracture prevention strategies. Acknowledgments Not Applicable. Author contributions YDJ: Conceptualization, Methodology, Writing – Original Draft Preparation, Supervision.WGY: Project Administration, Funding Acquisition, Supervision.All authors have read and agreed to the final version of the manuscript. Funding Not Applicable. Data availability No datasets were generated or analysed during the current study. Declarations Competing interests All authors have no conflicts of interest or financial ties to disclose. Ethical approval and consent to participate Ethical approval was not required. Consent for publication Not Applicable. Pre-registered clinical trial number Not Applicable. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.